Cargando…
Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?()
Autores principales: | Gupta, Kartik, Prejean, Shane P., Vaduganathan, Muthiah, Golwala, Harsh, Watts, Thomas Evan, Aryal, Sudeep R., von Mering, Gregory, Booker, Oscar Julian, Ahmed, Mustafa I., Bajaj, Navkaranbir S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859524/ https://www.ncbi.nlm.nih.gov/pubmed/31763435 http://dx.doi.org/10.1016/j.ijcha.2019.100404 |
Ejemplares similares
-
Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis
por: Bajaj, Navkaranbir S., et al.
Publicado: (2019) -
Complete versus culprit-vessel only revascularization in STEMI: An updated meta-analysis of randomized control trials
por: Gupta, Kartik, et al.
Publicado: (2020) -
Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
por: Bajaj, Navkaranbir S., et al.
Publicado: (2020) -
Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapy–An observational study
por: Holm, Anna, et al.
Publicado: (2021) -
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
por: Golwala, Harsh B, et al.
Publicado: (2018)